Growth Hormone Improves Short-Term Growth in Patients with Temple Syndrome.

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Temple syndrome is an imprinting disorder caused by maternal uniparental disomy of chromosome 14 (mat UPD14), paternal deletion of 14q32 or paternal hypomethylation of the intergenic differentially methylated region (MEG3/DLK1 IG-DMR).

Patients with Temple syndrome have pre- and postnatal growth restriction, short stature, hypotonia, small hands and feet and precocious puberty.

Who Took Part

The study group was 14 patients.

PubMed indexes the participants as infants, young children, children, teenagers and adults, both men and women.

This was a retrospective observational study reviewing the medical records of 14 patients with Temple syndrome, 7 of whom were treated with growth hormone.

What Was Measured

Topics PubMed links to this paper include Chromosomes, Human, Pair 14, DNA Methylation, Growth Disorders, Human Growth Hormone, Syndrome and Uniparental Disomy.

The authors tagged it with the keywords Imprinting disorder, Maternal uniparental disomy 14 and Temple syndrome.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.